



BAL PHARMA LIMITED

Corporate Office

+91 80 4137 9500

info@balpharma.com

5th Floor, Lakshmi Narayan Complex, 10/1,
Palace Road, Bangalore - 560 052, India.

To

Listing Compliance Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C/2, G
Block,
Bandra Kurla Complex, Bandra (E),
Mumbai-400051

To

BSE Limited
1st Floor, New Trading
Ring, Rotunda Building, P.J.
Towers, Dalal Street,
Mumbai – 400001

Date: September 24, 2026

Symbol: BALPHARMA

Scrip Code: 524824

Dear Sir,

Sub: Summary of the Proceedings / Outcome of the 39th Annual General Meeting ('AGM') held on 24th September 2026

Further to our letter dated August 26, 2026, sharing copy of the Notice of the 39th AGM of the Company dated August 12, 2026, we confirm that the AGM as scheduled was held today i.e., 24th September 2026 and the business mentioned in the said Notice were duly transacted.

In this regard, please find enclosed the proceedings as required under Regulation 30, Part A of Schedule - III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting commenced at 11:30 AM (IST) and concluded at 11:55 AM (IST) (including time allowed for e- voting at AGM).

Please take this intimation on record.

Thanking you

For Bal Pharma Limited



Shreepada ML

Company Secretary and Compliance officer

ICSI M No : A66681

Enclosure: As above

Registered Office : Plot No. 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099, Karnataka, INDIA.

Ph: +91 80 41570811/813.

CIN # L85110KA1987PLC008368

 www.balpharma.com



BAL PHARMA LIMITED

Corporate Office

+91 80 4137 9500

info@balpharma.com

5th Floor, Lakshmi Narayan Complex, 10/1,
Palace Road, Bangalore - 560 052, India.

To

Listing Compliance Department
National Stock Exchange of India
Limited,
Exchange Plaza, 5th Floor, Plot No. C/2,
G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai-400051

To

BSE Limited
1st Floor, New Trading
Ring, Rotunda Building,
P.J. Towers, Dalal Street,
Mumbai – 400001

Date: September 24, 2026

Symbol: BALPHARMA

Scrip Code: 524824

Dear Sir,

Sub: Summary of the Proceedings of 39th Annual General Meeting ('AGM') held on 24th September 2026

In compliance with the applicable provisions of the Companies Act, 2013 and the circulars issued by the Ministry of Corporate Affairs ("MCA") vide its Circular No.9 /2025 dated September 22, 2025 has allowed the Companies to conduct its Annual General Meeting through video conferencing ("VC") or other audio-visual means ("OAVM") till further orders, in accordance with the requirements laid down in Para 3 and Para 4 of the General Circular No. 20/2020 dated 05.05.2020 & in compliance with the applicable provisions of the Companies Act 2013 ("Act"), and foresaid circulars and guidelines issued in this regard, the Company has conducted the 39th Annual General Meeting (AGM) on Thursday , the 24th day of September , 2026 at 11.30 AM through Video Conferencing/ Other Audio Visual Means.

Directors and KMP present (all present through VC):

1. Mr. Shailesh Siroya – Managing Director
2. Mr. Ravindra Kumar Kothari – Director
3. Mr. Himesh Virupakshaya - Director
4. Mr. Jatish Sheth - Independent Director, Chairman of Audit Committee & Nomination and Remuneration Committee.
5. Dr. Mukesh Bheekamchand - Independent Director
6. Ms. Nicola Neeladri- Independent Director
7. Mr. Bharath Bhushan D V , Chief Financial Officer
8. Mr. Shreepada M L , Company Secretary

Registered Office : Plot No. 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099, Karnataka, INDIA.

Ph: +91 80 41570811/813.

CIN # L85110KA1987PLC008368

 www.balpharma.com



BAL PHARMA LIMITED

Corporate Office

+91 80 4137 9500

info@balpharma.com

5th Floor, Lakshmi Narayan Complex, 10/1,
Palace Road, Bangalore - 560 052, India.

Other Invitees in attendance (all present through VC):

1. Mr. Nikhil Kumar representing S S J N B & Co, Statutory Auditors,
2. Mr. Parameshwar G Bhat, Secretarial Auditor and also Scrutinizer for this Meeting.
3. Mr Vijayakrishna KT, Company Secretarial Adviser

Quorum of the Meeting:

58 Members were present at the meeting through video conferencing or other audio-visual means.

Proceedings of the Meeting:

Mr. Shailesh Siroya, Managing Director of the Company, was elected as the Chairman of the Meeting, having been proposed by Mr. Surendran V B, Member of the Company, and seconded by Mr. Nabajit Sarma, Member of the Company.

The Chairman welcomed all the Members, Directors, Auditors and other invitees who had joined the Meeting through VC/OAVM.

After ascertaining that the requisite quorum was present, the Chairman called the Meeting to order. The Chairman informed the Members that the Company had taken all feasible steps to enable the Members to participate in the AGM through VC/OAVM and to exercise their voting rights on the businesses set out in the Notice of the AGM. Thereafter, Mr. Shreepada M L, Company Secretary of the Company, briefed the Members regarding the general instructions for participation in the Meeting and the procedure for casting votes.

The Chairman then addressed the Members and briefed them on the performance of the Company during the Financial Year 2025-26. The Chairman informed the Members that M/s. S S J N B & Co., Chartered Accountants, Statutory Auditors, and Mr. Parameshwar G Bhat, Practising Company Secretary, Secretarial Auditor, had expressed unmodified opinions in their respective Audit Reports for the financial year ended March 31, 2026. Accordingly, the Statutory Auditors' Report and the Secretarial Audit Report were taken as read.

**BAL PHARMA LIMITED**

Corporate Office

+91 80 4137 9500

info@balpharma.com

5th Floor, Lakshmi Narayan Complex, 10/1,
Palace Road, Bangalore - 560 052, India.

The Chairman thereafter took the Notice of AGM and read out the following items of business, as per the Notice of AGM:

No.	Particulars	Resolution Type
Ordinary Business		
1	To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31, 2026, together with the Reports of the Board of Directors and the Auditors thereon.	Ordinary
2	To declare dividend of Rs. 1.20 per equity share of Rs. 10/- each for the Financial Year 2025-26.	Ordinary
3	To re-appoint Mr. Ravindra Kumar Kothari (DIN: 03418320), who retires by rotation, as a Director of the Company	Ordinary
Special Business		
4	To ratify the remuneration payable to the Cost Auditors for the Financial Year 2026-27.	Ordinary
5	To renew the contract with M/s. Desa Marketing International.	Ordinary
6	To approve the change in designation of Mr. Ravindra Kumar Kothari (DIN: 03418320) from Non-Executive Director to Whole-Time Director	Special
7	To approve the change in designation of Mr. Virupakshaya Himesh (DIN: 08554422) from Whole-Time Director to Non-Executive Director.	Special

The Chairman informed the Members that, as all the Resolutions had already been put to vote through remote e-voting, there would be no proposing or seconding of the Resolutions at the AGM and no voting by show of hands.

The Members were thereafter provided an opportunity to ask questions and express their views through VC/OAVM. Four speaker shareholders had registered to speak; however, none of the registered speakers addressed the Meeting.

Registered Office : Plot No. 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099, Karnataka, INDIA.

Ph: +91 80 41570811/813.

CIN # L85110KA1987PLC008368

 www.balpharma.com



BAL PHARMA LIMITED

Corporate Office

+91 80 4137 9500

info@balpharma.com

5th Floor, Lakshmi Narayan Complex, 10/1,
Palace Road, Bangalore - 560 052, India.

The Chairman further informed the Members that the voting results, together with the Scrutinizer's Report, would be submitted to the Stock Exchanges and placed on the Company's website within two working days from the conclusion of the AGM, in accordance with the applicable provisions of the Companies Act, 2013 and the SEBI Listing Regulations.

On behalf of the Board of Directors, the Chairman thanked all the Members for their participation in the 39th Annual General Meeting and for their continued trust and support to Bal Pharma Limited.

There being no other business to transact, the Chairman declared the proceedings of the 39th Annual General Meeting closed.

The Meeting concluded with a vote of thanks to the Members.

The meeting commenced at 11:30 AM (IST) and concluded at 11:55 AM (IST) (including time allowed for e- voting at AGM).

Please take this intimation on record.

Thanking you

For Bal Pharma Limited



Shailesh Siroya
Managing Director
DIN: 00048109

Registered Office : Plot No. 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099, Karnataka, INDIA.

Ph: +91 80 41570811/813.

CIN # L85110KA1987PLC008368

 www.balpharma.com